Certepetide is under clinical development by Lisata Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Certepetide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Certepetide overview
Certepetide (CEND-1) is under development for the treatment of solid tumors such as pancreatic cancer including pancreatic ductal adenocarcinoma, gastroesophageal junction carcinomas, appendiceal cancer, breast cancer, cancer, ovarian cancer, bile duct cancer (cholangiocarcinoma), gallbladder cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, glioblastoma multiforme, peritoneal carcinomatosis and metastatic colorectal cancer. The drug candidate is an internalized-arginylglycylaspartic acid cyclic peptide which acts by targeting neuropilin 1 receptor. It is administered through the intravenous route and is developed based on CendR Platform.
The drug candidate was also under development for breast cancer, prostate cancer, peritoneal cancer, non-small cell lung cancer, glioblastoma, hepatocellular carcinoma, recurrent head and neck cancer squamous cell carcinoma, appendiceal cancer oropharyngeal cancer, oral cavity (mouth) cancer, hypopharyngeal cancer, laryngeal cancer, esophageal squamous cell carcinoma (ESCC), triple-negative breast cancer, and ovarian cancer.
Lisata Therapeutics overview
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. The company-lead product certepetide (LSTA1) is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors. Lisata Therapeutics also carries out the research and development of various pipelines for indications such as first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), pancreatic, colon, and appendiceal cancers, cholangiocarcinoma, glioblastoma multiforme, locally advanced, non-resectable, gastroesophageal adenocarcinoma and others. The company utilizes its proprietary CD34+ cell therapy technology to develop therapies for ischemia diseases. It serves biotechnology, pharmaceutical and medical product companies and academic research institutions. Lisata Therapeutics is headquartered in Basking Ridge, New Jersey, the US.
For a complete picture of Certepetide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
